Search research articles
Contact Us
Filters
Showing results (11-20 of 192) with videos related to
Page
of 20
Sort By:
Nature Reviews. Clinical Oncology
|
September 1, 2019
Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine
Jonathan Kimmelman
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
December 14, 2007
Ethics at phase 0: clarifying the issues
Jonathan Kimmelman
Clinical Trials (London, England)
|
August 16, 2024
Commentary on Astrachan et al. The transmutation of research risk in pragmatic clinical trials
Jonathan Kimmelman
Handbook of Clinical Neurology
|
September 28, 2024
Ethics of gene and cell therapy development for neurologic disorders
Jonathan Kimmelman
Bioethics
|
January 19, 2011
Ethics, ambiguity aversion, and the review of complex translational clinical trials
Jonathan Kimmelman
BMJ (Clinical Research Ed.)
|
January 8, 2005
Recent developments in gene transfer: risk and ethics
Jonathan Kimmelman
Retina (Philadelphia, Pa.)
|
November 30, 2007
Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration
Jonathan Kimmelman
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
October 31, 2009
Tomorrow, interrupted? Risk, ethics, and medical advance in gene transfer
Jonathan Kimmelman
IRB
|
October 14, 2005
Medical research, risk, and bystanders
Jonathan Kimmelman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2016
Is Participation in Cancer Phase I Trials Really Therapeutic?
Jonathan Kimmelman
Page
of 20
Search research articles
Search
Showing results (11-20 of 192) with videos related to
Sort By:
Page
of 20
Nature Reviews. Clinical Oncology
|
September 1, 2019
Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine
Jonathan Kimmelman
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
December 14, 2007
Ethics at phase 0: clarifying the issues
Jonathan Kimmelman
Clinical Trials (London, England)
|
August 16, 2024
Commentary on Astrachan et al. The transmutation of research risk in pragmatic clinical trials
Jonathan Kimmelman
Handbook of Clinical Neurology
|
September 28, 2024
Ethics of gene and cell therapy development for neurologic disorders
Jonathan Kimmelman
Bioethics
|
January 19, 2011
Ethics, ambiguity aversion, and the review of complex translational clinical trials
Jonathan Kimmelman
BMJ (Clinical Research Ed.)
|
January 8, 2005
Recent developments in gene transfer: risk and ethics
Jonathan Kimmelman
Retina (Philadelphia, Pa.)
|
November 30, 2007
Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration
Jonathan Kimmelman
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
October 31, 2009
Tomorrow, interrupted? Risk, ethics, and medical advance in gene transfer
Jonathan Kimmelman
IRB
|
October 14, 2005
Medical research, risk, and bystanders
Jonathan Kimmelman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2016
Is Participation in Cancer Phase I Trials Really Therapeutic?
Jonathan Kimmelman
Page
of 20